Figure 5.
Treatment of levocarnitine and aluminum chloride on nitric oxide (NO) (A–F); in the prefrontal cortex (PFC) (A), striatum (ST) (B), parietal cortex (PC) (C), hypothalamus (HT) (D), hippocampus (HP) (E) and cerebellum (CB) (F). The groups were control, AlCl3 (aluminum chloride), AST (astaxanthin), AST+AlCl3 (aluminum chloride and astaxanthin) and AlCl3+LC (aluminum chloride and levocarnitine) and LC (levocarnitine). Data presented as mean ± SEM. n = 6 per group except AST (n = 3); and AlCL3+AST (n = 3); ∗∗∗p < 0.001, ∗∗p < 0.01, ∗p < 0.05.